{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:14:32Z","timestamp":1774358072378,"version":"3.50.1"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[1991,4,1]],"date-time":"1991-04-01T00:00:00Z","timestamp":670464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1991,4]]},"abstract":"<jats:p>Ro 09-1428, a new parenteral cephalosporin with a catechol moiety attached at position 7 of the cephalosporin ring, showed high in vitro activity against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, and Streptococcus pyogenes, with MICs for 90% of strains tested (MIC90s) of less than or equal to 0.39 micrograms\/ml. Morganella morganii, Providencia rettgeri, Citrobacter freundii, Haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae were inhibited with MIC90s of less than or equal to 3.13 micrograms\/ml. Serratia marcescens was less susceptible to Ro 09-1428, with a MIC90 of 25 micrograms\/ml. The most distinctive feature of Ro 09-1428 was its potent activity against Pseudomonas aeruginosa and Acinetobacter calcoaceticus, with MIC90s of 0.39 and 6.25 micrograms\/ml, respectively. Most of the ceftazidime-resistant strains of P. aeruginosa, E. cloacae, and C. freundii were inhibited by Ro 09-1428, while those of S. marcescens were resistant at a concentration of 12.5 micrograms\/ml. Ro 09-1428 was more active than ceftazidime against staphylococci. PBP 3 was the most sensitive target in E. coli and P. aeruginosa. The response to ferric iron in growth medium suggests that Ro 09-1428 may be taken up by transport mechanisms similar to those of other catechol cephalosporins. In accordance with its in vitro activity, Ro 09-1428 activity was equal to or greater than ceftazidime activity in efficacy against experimental septicemias in mice. The results indicate that Ro 09-1428 is a broad-spectrum cephalosporin with advantages over ceftazidime in its activity against P. aeruginosa, staphylococci, and ceftazidime-resistant strains of C. freundii and E. cloacae.<\/jats:p>","DOI":"10.1128\/aac.35.4.653","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:05:50Z","timestamp":1340841950000},"page":"653-659","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":22,"title":["In vitro and in vivo evaluation of Ro 09-1428, a new parenteral cephalosporin with high antipseudomonal activity"],"prefix":"10.1128","volume":"35","author":[{"given":"M","family":"Arisawa","sequence":"first","affiliation":[{"name":"Department of Chemotherapy and Biochemistry, Nippon Roche Research Center, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Sekine","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy and Biochemistry, Nippon Roche Research Center, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy and Biochemistry, Nippon Roche Research Center, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy and Biochemistry, Nippon Roche Research Center, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Angehrn","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy and Biochemistry, Nippon Roche Research Center, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R L","family":"Then","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy and Biochemistry, Nippon Roche Research Center, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.35.4.653","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.35.4.653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:19:06Z","timestamp":1645456746000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.35.4.653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,4]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1991,4]]}},"alternative-id":["10.1128\/AAC.35.4.653"],"URL":"https:\/\/doi.org\/10.1128\/aac.35.4.653","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,4]]},"assertion":[{"value":"1991-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}